Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2003
12/23/2003US6667337 Combination therapy for cancer
12/23/2003US6667319 Neuropeptide Y Y5 receptor antagonists
12/23/2003US6667317 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
12/23/2003US6667315 Pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates)
12/23/2003US6667297 Methods for treating neuropsychiatric disorders
12/23/2003US6667291 Endometrial Steroid Binding Protein II activity; endometrial and breast cancers
12/23/2003US6667156 Treating nervous system tumors; obtain cells, incubate with modulator, evaluate tumor propagtion
12/23/2003US6667064 Composition and method for treatment of hypertriglyceridemia
12/23/2003US6667057 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
12/23/2003US6667053 D and L etherlipid stereoisomers and liposomes
12/23/2003US6667042 Ciprofloxacin administered in three dosages forms with different release profiles; Cmax is reached in < about twelve hours
12/23/2003US6667041 Use of neurotoxin therapy for treatment of urologic and related disorders
12/23/2003US6667025 Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
12/23/2003US6667024 Kit comprising molecule with radioisotope binding site linked to antigen-binding fragment of antibody that specifically binds to tumor associated antigen, and metal chelator and basic amino acid or peptide clearing agents
12/23/2003CA2302232C Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
12/19/2003WO2002101076A2 Methods for targeted expression of therapeutic nucleic acid
12/19/2003CA2460095A1 Methods for targeted expression of therapeutic nucleic acid
12/18/2003WO2003104818A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
12/18/2003WO2003104480A1 Method for identifying agonists or antagonists for the gpr45-like/gpr63 receptor
12/18/2003WO2003104459A1 Fcyriia transgenic animal model for autoimmune disease
12/18/2003WO2003104256A2 THE CaR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003103822A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103771A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003WO2003103770A2 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103712A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003WO2003103701A1 Compositions and methods for treating diabetes
12/18/2003WO2003103699A1 Use of ramoplanin to treat diseases associated with the use of antibiotics
12/18/2003WO2003103696A1 Cardiac glycosides for treating muscle pain and spasm
12/18/2003WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003WO2003103690A1 Antithrombogenic platiniferous ceramic composition and article containing the same
12/18/2003WO2003103688A1 A stable bicarbonate-based solution in a single container
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103679A1 Use of devazepide in combination with an opioid analgesic for potentiating the effect of the analgesic
12/18/2003WO2003103676A2 Method of treating cancer using kinase inhibitors
12/18/2003WO2003103672A1 Sequential therapy comprising a 20(s)-camptothecin and an anthracycline
12/18/2003WO2003103664A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103659A1 Therapeutic agent for overactive bladder
12/18/2003WO2003103650A1 Active ingredient salts and esters of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol
12/18/2003WO2003103644A2 Guanidino phenylalanin compounds used as urokinase inhibitors
12/18/2003WO2003103643A1 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
12/18/2003WO2003103640A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
12/18/2003WO2003103633A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003WO2003103632A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003WO2003103614A2 Method and compositions for the treatment of edematous-firbrsclerotic panniculopathy
12/18/2003WO2003103613A2 Induction of insulin expression
12/18/2003WO2003103602A2 Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003WO2003103581A2 Compositions and methods for liver growth and liver protection
12/18/2003WO2003103478A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003086323A3 Compositions and methods for immunomodulation
12/18/2003WO2003086267A3 Multi-phase, multi-compartment capsular system
12/18/2003WO2003077881A3 Method for production of phytoalexins
12/18/2003WO2003074558A3 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
12/18/2003WO2003074027A3 Self emulsifying drug delivery systems for poorly soluble drugs
12/18/2003WO2003068207A3 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
12/18/2003WO2003063927A3 Compositions and methods to treat gastrointestinal disorders
12/18/2003WO2003061704A3 Combination therapy for the treatment of bacterial infections
12/18/2003WO2003059329A3 Polytartrate composition
12/18/2003WO2003057911A3 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
12/18/2003WO2003057159A3 Psoriasin expression by breast epithelial cells
12/18/2003WO2003053431A3 Pharmaceutical compositions based on azetidine derivatives
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003051307A3 Materials and methods for the treatment or prevention of obesity
12/18/2003WO2003051301A3 USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003050064B1 Mitotic kinesin inhibitors
12/18/2003WO2003040726A3 Screening for hepatitis c virus entry inhibitors
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003032926A3 Compositions and methods for reversal of drug resistance
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003026558A3 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
12/18/2003WO2003013536A3 Methods for treatment of cancer using irinotecan based on ugt1a1
12/18/2003WO2003006045A3 Cxcl10 treatment of secondary tissue degeneration
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002100899A3 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/18/2003WO2002097045A3 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/18/2003WO2002092788A3 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002067941A8 Combination comprising a signal transduction inhibitor and an epothilone derivative
12/18/2003WO2002067916A3 Pharmaceutical salts
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002054072A3 Assay to determine efficacy of treatment for mycobacterial infection
12/18/2003WO2002041883A3 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002032435A9 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
12/18/2003WO2002030257A9 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003US20030232944 Applying to the tissue formulation comprising first precursor component second precursor component comprises electrophilic component which crosslink at physiological temperatures over a period of time following application
12/18/2003US20030232889 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232876 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
12/18/2003US20030232864 Novel Compounds and compositions as protease inhibitors
12/18/2003US20030232863 Cathepsin cysteine protease inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
1 ... 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 ... 1151